Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glyceraldehyde 3 phosphate dehydrogenase pseudogene 29 (GAPDHP29) is one of multiple human pseudogenes related to the canonical GAPDH gene, originally formed by duplication or retrotransposition events in the genome. Unlike the functional GAPDH enzyme, which is central to glycolysis and various signaling pathways[1], GAPDHP29 does not encode a functional protein and does not have known biological functions or disease associations. Pseudogenes of GAPDH are abundant in vertebrate genomes, but most, including GAPDHP29, appear to be transcriptionally silent and functionally inert[2][3]. In summary, "glyceraldehyde 3 phosphate dehydrogenase pseudogene 29" is not a therapeutic target, is not a functional receptor or enzyme, and represents a non-coding genomic element with no established functions, disease roles, or drug interactions[2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glyceraldehyde 3 phosphate dehydrogenase pseudogene 29 (GAPDHP29).